Drug Profile
Bevacizumab biosimilar - Essex Bio-Technology/Shanghai Henlius Biotech
Alternative Names: Bevacizumab injection; EB 12 20145P; Hanbeitai; HLX 04; HLX04-O; rhuMAb-VEGF biosimilar - Shanghai Henlius BiotechLatest Information Update: 19 Jan 2024
Price :
$50
*
At a glance
- Originator Shanghai Henlius Biotech
- Developer Eurofarma; Shanghai Henlius Biotech
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer
- Phase III Wet age-related macular degeneration
- Phase II Liver cancer
- No development reported Diabetic retinopathy; Solid tumours
Most Recent Events
- 17 Jan 2024 Efficacy and adverse events data from a phase II/III trial in Colorectal cancer released by Shanghai Henlius Biotech
- 13 Mar 2023 Henlius Biotech completes a phase I/II trial for Wet age-related macular degeneration in China (Intravitreous) (NCT04993352)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Diabetic-retinopathy in China (IV, Injection)